Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 14Terminated 5Recruiting 4Withdrawn 2Unknown 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Breast 1

Conditions

Brain Neoplasms 101Glioblastoma 85Glioma 58Central Nervous System Neoplasms 34Astrocytoma 27Neuroblastoma 26Gliosarcoma 19Breast Neoplasms 19Neoplasms 18Oligodendroglioma 17Recurrence 14Neoplasm Metastasis 13Medulloblastoma 12Ependymoma 11Carcinoma, Non-Small-Cell Lung 11Lymphoma 9Sarcoma 8Osteosarcoma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Neuroma, Acoustic 7Meningioma 7Lymphoma, Non-Hodgkin 7Lymphoma, Follicular 7Lung Neoplasms 7Hodgkin Disease 7Burkitt Lymphoma 7Wilms Tumor 6Sezary Syndrome 6Neuroectodermal Tumors, Primitive 6Mycosis Fungoides 6

Interventions

tucatinib 1pembrolizumab 1XENP 1595 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Central Nervous System Diseases × CNS × Clear all
NCT05321498 2023-09-28

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

Inmune Bio, Inc.

Phase 2 Withdrawn
CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Tauopathies, Cognitive Dysfunction

NCT04512261 2022-07-01

TOPAZ

Cedars-Sinai Medical Center

Phase 1/2 Withdrawn
BreastCNS

Brain Neoplasms, Breast Neoplasms, Central Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡